Novartis news

Novartis receives approval in Switzerland for Celtura®, a cell culture-based Influenza A(H1N1) pandemic vaccine

Novartis launches Prevacid®24HR over-the-counter for full 24-hour frequent heartburn treatment

Novartis receives regulatory approval in Germany for Celtura®, a cell culture-based Influenza A(H1N1) pandemic vaccine

Novartis to expand its human vaccines presence in China through proposed acquisition of a majority stake in Zhejiang Tianyuan

Novartis announces USD 1 billion investment to build largest pharmaceutical R&D institute in China

Novartis on track to deliver Influenza A (H1N1) vaccine for the US

Novartis biological drug Ilaris® approved in EU to treat children and adults with CAPS, a rare debilitating auto-inflammatory disease

Novartis receives approval in the European Union for Exforge HCT®, a new 3-in-1 treatment for high blood pressure

Novartis delivers strong new product momentum and operational performance in first nine months of 2009

New Phase II data show ACZ885 gave better pain relief and flare prevention for patients with chronic gout than an injectable corticosteroid